X4 Pharmaceuticals director files initial Form 3

Accepted by SEC EDGAR 07/01/2026 - 04:18 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

X4 Pharmaceuticals, Inc. director Gold Kelly has filed an initial statement of beneficial ownership on Form 3 for X4 Pharmaceuticals, Inc. This filing lists Kelly as a director and does not report any insider transactions or derivative positions in the company’s securities.

Key Terms

Form 3, beneficial ownership, director

3 terms

Form 3 regulatory

"has filed an initial statement of beneficial ownership on Form 3"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

beneficial ownership financial

"has filed an initial statement of beneficial ownership on Form 3"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

director financial

"shows that Gold Kelly is a director and is reporting initial"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the XFOR Form 3 filing by Gold Kelly represent?

The Form 3 for X4 Pharmaceuticals, Inc. shows that Gold Kelly is a director and is reporting initial beneficial ownership status. It is a baseline disclosure and does not show any insider trades or derivative positions in the company’s securities.

Does the XFOR Form 3 for Gold Kelly show any stock transactions?

No, the Form 3 for Gold Kelly reports no insider stock transactions. The transaction summary shows zero buys, sells, exercises, gifts, or other dispositions, indicating only an initial ownership disclosure rather than trading activity.

What role does Gold Kelly have at X4 Pharmaceuticals (XFOR)?

Gold Kelly is identified as a director of X4 Pharmaceuticals, Inc. in the Form 3 filing. The report confirms director status and serves as an initial beneficial ownership statement, without detailing any specific holdings or trades in company securities.

Are there any derivative securities reported in the XFOR Form 3?

No derivative securities are reported in this Form 3. The derivative summary is empty and the transaction summary shows zero derivative transactions, indicating no reported options, warrants, or similar instruments for Gold Kelly in this filing.

Does the XFOR Form 3 mention any Rule 10b5-1 trading plan for Gold Kelly?

The Form 3 does not indicate any Rule 10b5-1 trading plan for Gold Kelly. Footnotes are effectively empty, and the transaction summary shows no trades, so there is no reference to pre-arranged trading arrangements in this disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Gold Kelly

(Last) (First) (Middle)

C/O X4 PHARMACEUTICALS, INC.

61 NORTH BEACON STREET, 4TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02134

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
07/01/2026

3. Issuer Name and Ticker or Trading Symbol
X4 Pharmaceuticals, Inc [ XFOR ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit List: Exhibit 24 Power of Attorney

No securities are beneficially owned.

	/s/ David Kirske, Attorney-In-Fact	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)